Sugi Predict

Sugi Predict / Compounds / SCHEMBL212031

SCHEMBL212031

SCHEMBL212031

CC(C)(C)OC[C@@H](NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 6/20 0.53
▸ GRN P28799 1/20 0.52
▸ SORT1 Q99523 1/20 0.52
▸ PPARG P37231 5/20 0.51
▸ CTSK P43235 9/20 0.49
▸ CTSS P25774 6/20 0.49
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ ACE P12821 1/20 0.46
▸ PPARD Q03181 2/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213064 1.00 PPARA (0.53) PPARAGRNSORT1PPARGCTSK
SCHEMBL2158663 1.00 PPARA (0.53) PPARAGRNSORT1PPARGCTSK
SCHEMBL31276763 0.94 PPARA (0.49) PPARAGRNSORT1PPARGCTSK
SCHEMBL20592494 0.88 PPARA (0.50) PPARAGRNSORT1PPARGCTSK
SCHEMBL20592496 0.88 PPARA (0.50) PPARAGRNSORT1PPARGCTSK
SCHEMBL29770564 0.88 PPARA (0.45) PPARAGRNSORT1PPARGCTSK
SCHEMBL27587953 0.87 GRN (0.54) PPARAGRNSORT1PPARGCTSK
SCHEMBL27587952 0.87 GRN (0.54) PPARAGRNSORT1PPARGCTSK
SCHEMBL588912 0.86 PPARA (0.53) PPARAPPARGCTSKCTSSCTSL
SCHEMBL580779 0.86 PPARA (0.53) PPARAPPARGCTSKCTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058855-A Preparation method of Mebamamide C 深圳连续制药科技有限公司 2025-05-30 — — CN claimed
EP-2621919-B1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-01-13 — — EP claimed
US-8759374-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-06-24 — — US claimed
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2012-05-31 — — US claimed
CN-120058855-A Preparation method of Mebamamide C 深圳连续制药科技有限公司 2025-05-30 — — CN disclosed
CN-120058855-A Preparation method of Mebamamide C 深圳连续制药科技有限公司 2025-05-30 — — CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
EP-4405352-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2024-07-31 — — EP disclosed
CN-117980303-A Novel compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-05-03 — — CN disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
US-11667674-B2 Antibacterial cyclic lipopeptides VERSITECH LIMITED (CN) 2023-06-06 — — US disclosed
US-20230159475-A1 COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2023-05-25 — — US disclosed
US-6844366-B2 Sulfonamide hydroxamates SYNTEX (U.S.A.) LLC (US) 2005-01-18 — — US disclosed
US-6787559-B2 HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR SYNTEX (U.S.A.) LLC. 2004-09-07 — — US disclosed
EP-1149072-B1 SULFONAMIDE HYDROXAMATES HOFFMANN LA ROCHE (CH) 2004-06-30 — — EP disclosed
US-20030216405-A1 Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor BILLLEDEAU ROLAND JOSEPH (US) 2003-11-20 — — US disclosed
US-20030199520-A1 Sulfonamide hydroxamates BILLLEDEAU ROLAND JOSEPH (US) 2003-10-23 — — US disclosed
US-6492394-B1 PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES SYNTEX (U.S.A.) LLC 2002-12-10 — — US disclosed
EP-1149072-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 — — EP disclosed
WO-2000037436-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216405-A1 Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor CTSE, PREP, HPN PPARA 1574/4885GRN 2021/4885SORT1 1212/4885
US-20030199520-A1 Sulfonamide hydroxamates MMP3, TIMP3, MMP13 PPARA 780/4885GRN 1607/4885SORT1 438/4885
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 PPARA 1285/4885GRN 2196/4885SORT1 2327/4885
US-11667674-B2 Antibacterial cyclic lipopeptides PTMS, NRDC, LNPEP PPARA 90/4885GRN 3088/4885SORT1 2474/4885
US-20230159475-A1 COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF CD47, CD74, ICOS PPARA 1046/4885GRN 839/4885SORT1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.